Abstract
The σ receptors are regarded as unique binding sites, distinct from opiate and PCP receptors and implicated in higher brain function. They were classified into σl and σ2 subtypes, the former was cloned from rodent and human tissues while the latter has not yet been fully characterized. Although the precise mechanism of the functional response of σ receptors is still uncertain, it has been accepted that they can modulate a number of central neurotransmitter systems, including glutamate/NMDA, serotonergic, dopaminergic, noradrenergic routes, as well as some other signaling pathways (e.g. neurotrophin and growth factor signaling) which are seemingly important for the brain function. In accordance with their modulatory role, σ receptor ligands have been proposed to be useful in several therapeutic areas such as schizophrenia, depression and anxiety, amnesic and cognitive deficits, drugs of abuse. The present review summarizes the findings related to the pharmacological effects and potential activity of σ receptor ligands from behavioral models predictive of some neuropsychiatric disorders.
Keywords: σ1- and σ2-receptor ligands, behavioral effect, dopamine (DA) agonists, phencyclidine (PCP), prepuls inhibition (PPI), forced swim test (FST), olfactory bulbectomy (OB), anxiety, cocaine, learning and memory
Current Pharmaceutical Design
Title: Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Volume: 18 Issue: 7
Author(s): Grazyna Skuza
Affiliation:
Keywords: σ1- and σ2-receptor ligands, behavioral effect, dopamine (DA) agonists, phencyclidine (PCP), prepuls inhibition (PPI), forced swim test (FST), olfactory bulbectomy (OB), anxiety, cocaine, learning and memory
Abstract: The σ receptors are regarded as unique binding sites, distinct from opiate and PCP receptors and implicated in higher brain function. They were classified into σl and σ2 subtypes, the former was cloned from rodent and human tissues while the latter has not yet been fully characterized. Although the precise mechanism of the functional response of σ receptors is still uncertain, it has been accepted that they can modulate a number of central neurotransmitter systems, including glutamate/NMDA, serotonergic, dopaminergic, noradrenergic routes, as well as some other signaling pathways (e.g. neurotrophin and growth factor signaling) which are seemingly important for the brain function. In accordance with their modulatory role, σ receptor ligands have been proposed to be useful in several therapeutic areas such as schizophrenia, depression and anxiety, amnesic and cognitive deficits, drugs of abuse. The present review summarizes the findings related to the pharmacological effects and potential activity of σ receptor ligands from behavioral models predictive of some neuropsychiatric disorders.
Export Options
About this article
Cite this article as:
Skuza Grazyna, Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436458
DOI https://dx.doi.org/10.2174/138161212799436458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Approaches to Treating Cancer: Medicinal Chemistry and Therapeutic Potential (Guest Editor: David J. Weber)]
Current Topics in Medicinal Chemistry Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment
Current Pharmaceutical Biotechnology Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets Melatonin and Melatonin Agonists as Adjunctive Treatments in Bipolar Disorders
Current Pharmaceutical Design Medicinal Plants for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry PLGA Hollow Microbubbles Loaded with Iron Oxide Nanoparticles and Doxorubicin for Dual-mode US/MR Imaging and Drug Delivery
Current Nanoscience Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry Anticarcinogenic Actions of Tributyrin, A Butyric Acid Prodrug
Current Drug Targets Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Recent Developments in Taxane Drug Delivery
Current Drug Delivery Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Clinical Cancer Drugs